Analyses of factors involved in bone remodeling and inflammation in Ankylosing Spondylitis (AS) patients undergoing etanercept therapy
- Conditions
- M45.00
- Registration Number
- DRKS00004838
- Lead Sponsor
- Rheumazentrum Prof. Dr. med. G. Neeck
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 56
Inclusion Criteria
AS patients meeting the criteria of the European Spondyloathropathy Study Group and eligible for treatment with Etanercept and healthy control individuals
Exclusion Criteria
Not meeting the inclusion criteria healthy control individuals demonstrating obvious signs of inflammation
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determination of erythrocyte sedimentation rate (ESR, lab results) prior to the start of therapy and after 4 and 12 weeks of treatment. Calculation of disease activity (BASDAI) through the evaluation of questionnaires filled out prior to the start of therapy and after 12 weeks of treatment.
- Secondary Outcome Measures
Name Time Method